Seminar Briefing

Gonzalez-Esuerra, J., Karlsberg, S. and Paling, S.

Seminar Briefing
February 2020

The NHS Improvement Economics team is part of the Strategy Directorate in NHS Improvement. NHS Improvement aims to implement changes to help improve both quality and efficiency. Recent research by the Economics team intended to support this has included research on A&E performance, NHS staffing, and inpatient falls.

Smith, P.

Seminar Briefing
February 2020

Health System Strengthening (HSS) is an important concept now widely discussed, but too often without sufficient structure or an adequate understanding of what actually is involved. The articles on which this seminar is based (Morton, Thomas and Smith, 2016; Smith and Yip, 2016) attempted to present more clearly just what health system strengthening might entail and whether that might be modelled.

Pearson, S.

Seminar Briefing
February 2019

Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available publicly. This is exciting, but also offers serious and critical challenges in valuation. The focus of this seminar briefing is on those challenges.

Timmins, N.

Seminar Briefing
October 2018

This OHE publication by Nick Timmins, a senior fellow at the Institute for Government and the Kings Fund, sets out arguments in favour and against. It is based on the seminar he gave at OHE in July 2018.

Owen. G and Hopkins, M.

Seminar Briefing
April 2018

This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2) why the UK biotech firms that do exist have not brought blockbuster drugs to the market and (3) what the implications are for industrial strategy after Brexit. These remarks are based primarily on research we completed for our recent book, Science, the State and the City (Owen and Hopkins, 2016), with some additions and specific observations about the potential effects of Brexit.

Mullin, C.

Seminar Briefing
January 2018

This seminar focuses on the NHS staffing markets and the use of temporary staff, specifically in the NHS provider sector, i.e. foundation trusts and NHS trust. (which include hospitals). To provide background and context, the discussion begins with an overview of the NHS labour market and the role of staffing agencies in providing temporary staff. The core of the seminar is an examination of previous strong growth in expenditure on such staffing, particularly during the early part of this decade; the effects to date of government intervention to address that spending; and possible lessons for other sectors from the limited evidence now available.

Grabowski, D.

Seminar Briefing
August 2017

This OHE Seminar Briefing summarises a seminar given by Professor David Grabowski, which provided a health economics perspective on how payment and delivery interventions can encourage high-value nursing home care. It took lessons from the U.S. effort to encourage high-value care and applied them to the UK, where we have similarly relied on regulation as the key guarantor of quality.

 

Hicks, N.

Seminar Briefing
February 2017

This OHE Seminar Briefing summarises a seminar given by Dr Nicholas Hicks, Co-founder and Chief Executive of COBIC (Capitated Outcomes-Based Incentivised Care). Dr Hicks describes COBIC’s outcomes-centred approach that has been adopted by NHS services across England and that brings together commissioners, providers, other professions, patients and carers.

Siciliani, L.

Seminar Briefing
June 2016

This OHE Seminar Briefing summarises a seminar given by Professor Luigi Siciliani on waiting time policies in the health sector from an international perspective, and highlights which policies have worked well in the last decade in OECD countries. Professor Siciliani also touches on methods for comparing waiting times internationally and where the UK stands in the international figures. Finally, the Briefing discusses waiting time inequality by socioeconomic status.

Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.

Seminar Briefing
October 2015

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.

Pages

Subscribe to RSS - Seminar Briefing